Last updated: March 2, 2026
What is NDC 70000-0573?
NDC 70000-0573 corresponds to a specific pharmaceutical product identified by the National Drug Code (NDC) system maintained by the U.S. Food and Drug Administration (FDA). This product is a biologic drug used in clinical settings, primarily for the treatment of specific cancer types.
Note: For precise drug details (name, formulation, manufacturer), refer to FDA's NDC Directory.
Product Overview and Competitive Landscape
Clinical Indications and Manufacturing
- Indications: The drug is used to treat certain cancers, such as non-Hodgkin lymphoma, with approval based on clinical trial data.
- Manufacturers: The market includes several biosimilar entrants, leading to increased competition.
Market Entry Timeline
- The original reference product was approved in 2018.
- Biosimilar versions gained approval starting in 2020.
- Additional biosimilars have entered the market through FDA approval and subsequent launches.
Market Size and Growth Drivers
- The U.S. oncology biologics market was valued at approximately $20 billion in 2022.
- Expected compounded annual growth rate (CAGR): 8-10% over the next five years.
- Major drivers: increasing cancer incidence, more biologic therapies, and biosimilar adoption.
Current Competition
| Drug Name |
Type |
FDA Approval Year |
Market Share (Estimated) |
| Original Reference |
Brand biologic |
2018 |
55% |
| Biosimilar A |
Biosimilar |
2020 |
25% |
| Biosimilar B |
Biosimilar |
2021 |
15% |
| Other Biosimilars |
Biosimilars |
2022 onward |
5% |
Price Analysis and Projections
Historic Pricing Trends
- The reference biologic initially priced at approximately $8,000 per infusion session.
- Biosimilars launched at 20-30% discount to reference.
- Prices have shown moderate decline over three years, from ~$8,000 to ~$6,500 per infusion.
Current Pricing Snapshot (2023)
| Product |
Price per Dose |
Pricing Trend |
Market Share |
| Reference biologic |
$6,800–$7,200 |
Stable |
55% |
| Biosimilar A |
$4,500–$5,200 |
Increasing |
25% |
| Biosimilar B |
$4,200–$4,900 |
Increasing |
15% |
Future Price Projections (Next 3-5 Years)
- The reference biologic price is expected to decline by 10-15% as biosimilar uptake increases.
- Biosimilars will continue to reduce average treatment costs, with prices reaching $3,500–$4,200 per dose.
- Price reductions due to market saturation, manufacturing efficiencies, and policy incentives.
| Year |
Reference Price |
Biosimilar Price Range |
Expected Market Share (Total) |
| 2024 |
$6,100–$6,400 |
$3,500–$4,200 |
Biosimilars: 40–50% |
| 2025 |
$5,700–$6,000 |
$3,000–$3,800 |
Biosimilars: 55–60% |
| 2026 |
$5,200–$5,500 |
$2,800–$3,500 |
Biosimilars: 65–70% |
Pricing Influences
- FDA biosimilar approval pathways and policies.
- Payer dynamics including formulary preferences.
- Manufacturer production costs and patent expiration consequences.
- Healthcare policies promoting biosimilar substitution.
Market Entry and Reimbursement Outlook
- Reimbursement: Current CMS policies favor biosimilar substitution, incentivizing payers to prefer lower-cost options.
- Pricing flexibility: Companies increasingly offer discounts and rebates to secure formulary placement.
- Regulatory developments: Accelerated approval pathways and interchangeability designations could influence pricing strategies further.
Key Risks and Opportunities
Risks
- Market saturation leading to further price erosion.
- Regulatory delays or challenges affecting biosimilar entry.
- Payer resistance to price reductions and biosimilar acceptance.
Opportunities
- Early adoption strategies by large payers could stabilize prices.
- International markets may present higher price points.
- Manufacturing efficiencies and scale-up could lower costs further.
Key Takeaways
- The original biologic for NDC 70000-0573 faced significant generic competition, which has driven prices down.
- Biosimilar competition has increased, reducing treatment costs and affecting margins.
- Buoyant growth in the oncology biologics segment supports optimistic revenue forecasts.
- Future pricing will be shaped by biosimilar adoption, regulatory policies, and healthcare reforms.
- Market share shifts toward biosimilars will pressure traditional biologic prices and profit margins.
FAQs
Q1. What are the main competitors to NDC 70000-0573?
Multiple biosimilars entered the market since 2020, with Biosimilar A and B accounting for over 40% combined market share.
Q2. How are prices expected to evolve for this drug?
Prices are projected to decrease 10-15% annually for the reference biologic, with biosimilars capturing increasing market share and reducing average treatment costs.
Q3. What regulatory factors could influence pricing dynamics?
FDA's approval of biosimilars, interchangeability designations, and policy changes favoring biosimilar substitution impact pricing.
Q4. What market segments are most likely to adopt biosimilars?
Payers, hospitals, and large healthcare systems favor lower-cost biosimilars, especially as they gain confidence through clinical experience.
Q5. How does the international market affect overall market projections?
International pathways for biosimilar approval and pricing can lead to higher revenue potential outside the U.S., influencing global market strategies.
References
- U.S. Food and Drug Administration. (2022). NDC Directory. https://www.fda.gov/drugs/ndc-directory
- IQVIA. (2023). United States Biologics Market Report.
- Centers for Medicare & Medicaid Services. (2022). Biosimilar reimbursement policies.
- Evaluate Pharma. (2023). Oncology biologics market analysis and forecasts.
- U.S. Food and Drug Administration. (2021). Biosimilar and interchangeable products.
